- Home
- TEI vs SERA Comparison
TEI vs SERA Comparison
Compare TEI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | SERA |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.6M | 130.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TEI | SERA |
|---|---|---|
| Price | $6.31 | $3.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 142.4K | 57.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | N/A | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $4.35 | $1.37 |
| 52 Week High | $5.39 | $9.13 |
Technical Indicators
Market Signals| Indicator | TEI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 57.92 |
| Support Level | $6.31 | $3.20 |
| Resistance Level | $6.43 | $3.70 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 0.00 | 76.93 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.